Patents
Literature
13 results about "Interleukin 13" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Interleukin 13 (IL-13) is a protein that in humans is encoded by the IL13 gene. IL-13 was first cloned in 1993 and is located on chromosome 5q31 with a length of 1.4kb. It has a mass of 13 kDa and folds into 4 alpha helical bundles. The secondary structural features of IL-13 are similar to that of Interleukin 4 (IL-4); however it only has 25% sequence homology to IL-4 and is capable of IL-4 independent signaling. IL-13 is a cytokine secreted by T helper type 2 (Th2) cells, CD4 cells, Natural killer T cell, Mast cell, Basophil cells, Eosinophil cells and Nuocyte cells. Interleukin-13 is a central regulator in IgE synthesis, goblet cell hyperplasia, mucus hypersecretion, airway hyperresponsiveness, fibrosis and chitinase up-regulation. It is a mediator of allergic inflammation and different diseases including asthma.
Anti-il-13 antibody and use thereof
PCT designated stageWO2026086810A1Hybrid immunoglobulinsImmunoglobulins against cytokines/lymphokines/interferonsDiseaseAntiendomysial antibodies
The present disclosure relates to an anti-interleukin 13 (IL-13) antibody and the use thereof, and specifically relates to an antibody or antigen-binding fragment thereof that specifically binds to human IL-13, a multispecific antigen-binding molecule, an isolated nucleic acid molecule, a vector, a cell, a pharmaceutical composition, the pharmaceutical use, a method for treating a disease, etc. The anti-IL-13 antibody of the present disclosure can significantly inhibit IL-13-induced proliferation of TF-1 cells, can specifically bind to human IL-13 proteins and has relatively high affinity.
Owner:HAINAN SIMCERE PHARMA CO LTD
Fusion protein comprising il13
The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.
Owner:SYNERKINE PHARMA BV
A fusion protein comprising IL13
The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. 5 The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration. 20 26 21 41 00 10 A ug 2 02 6 1 0 A u g 2 0 2 6 2 0 2 6 2 1 4 1 0 0
Owner:SYNERKINE PHARMA BV
Il-13 antigen binding proteins
PCT designated stageWO2026114819A1Immunoglobulins against cytokines/lymphokines/interferonsImmunological disordersWhite blood cellAntigen binding
The present disclosure relates to antigen binding proteins that bind to one or more cytokines. In particular, the present disclosure provides interleukin 13 (IL-13) binding proteins as well as multispecific antigen binding proteins comprising an IL-13 binding domain. The present disclosure further relates to the use of said binding proteins in medicine.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Antibodies binding interleukin 13 and TSLP or tslpr and methods of use thereof
PendingCN121816362AImmunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against growth factorsDiseaseAntiendomysial antibodies
Described herein are novel bispecific antibodies that bind to interleukin 13 (IL-13) and TSLP or TSLPR and methods of use thereof. In certain aspects, described herein are methods of inhibiting the biological activity of IL-13 and TSLP or TSLPR. In certain aspects, described herein are pharmaceutical compositions comprising a bispecific antibody that binds to interleukin 13 (IL-13) and TSLP or TSLPR. In certain aspects, the antibodies and methods described herein are useful for the treatment of inflammatory diseases or disorders associated with elevated levels of IL-13 and / or IgE as well as TSLP or TSLPR.
Owner:PARAGON THERAPEUTICS INC
Therapeutic variable domain of heavy chain (VHH) antibodies neutralizing interleukin 13 (il-13)
The present invention provides VHH antibodies that neutralize the pro-inflammatory cytokine interleukin IL-13 and their uses for treatment of inflammatory, fibrotic and other diseases and disorders.
Owner:MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV
Methods of administering antibodies that bind interleukin 13
PCT designated stageWO2026080829A1Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesAtopic dermatitis
Described herein are methods of administration of antibodies that bind interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disorder or disease, such as atopic dermatitis.
Owner:APOGEE THERAPEUTICS INC
Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
PCT designated stageWO2026085419A3Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesWhite blood cell
Described herein are compositions and combinations comprising an antibody that binds Interleukin 13 (IL-13) and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient.
Owner:APOGEE THERAPEUTICS INC
Pharmaceutical formulations of antibodies that bind interleukin 13
Pharmaceutical formulations of interleukin (IL)-13 antibodies are described herein. Pharmaceutical formulations for use in treating an inflammatory disorder or disease are also provided.
Owner:TINGFENG THERAPY CO LTD
Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
PCT designated stageWO2026085419A2Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesWhite blood cell
Described herein are compositions and combinations comprising an antibody that binds Interleukin 13 (IL-13) and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient.
Owner:APOGEE THERAPEUTICS INC
Antibodies that bind interleukin 13 and methods of use
PendingEP4540284A4Peptide/protein ingredientsDigestive systemAntiendomysial antibodiesWhite blood cell
Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL- 13 and / or IgE.
Owner:APOGEE THERAPEUTICS INC
Antibodies that bind interleukin 13 and methods of use.
Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL- 13 and / or IgE.
Owner:APOGEE BIOLOGICS INC
Methods of administering antibodies that bind to interleukin 13
PendingCN121241066AImmunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesWhite blood cell
Described herein are methods of administering and methods of using antibodies that bind to interleukin 13 (IL-13). In certain aspects, methods of inhibiting the biological activity of IL-13 are described herein. In certain aspects, the antibodies and methods described herein are useful for the treatment of inflammatory disorders or diseases.
Owner:TINGFENG THERAPY CO LTD